Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (6225)	11/6/1998 2:43:00 PM
From: HoodBuilder	Read Replies (1) \| Respond to of 9523

NEW YORK, Nov 6 (Reuters) - Pfizer Inc. disclosed on Friday several early-stage experimental drugs and said it would add a new warning to labels of its blockbuster impotence drug Viagra. Pfizer said it had noted a slight incidence of priapism, or persistent erection, in Viagra patients, and mention of a slight risk would be added to labels on the drug. Pfizer also said it was near to opening a Phase I trial of its head trauma drug CP-101,606 and said it was exploring the use of a compound derived from worm protein, UK-279,276, as a candidate for treating stroke. Another name for PRIAPISM is Lucky